12:00 AM
Mar 18, 2002
 |  BioCentury  |  Emerging Company Profile

U3: Targets from the black box

Axel Ullrich has been a well-known figure in biotech for some 25 years. His research not only led to the identification of a number of cellular pathways controlling growth, as well as to Herceptin and recombinant insulin, but to a number of companies as well: Sugen Inc., his first enterprise, and VirGene Pharmaceuticals AG, now Axxima AG.

Last year he started his third company, U3 Pharma AG, based on new findings in signal transduction pathways coming out of his lab at the department of molecular biology at the Max-Planck-Institute for Biochemistry.

"The work led to new targets, and Ullrich was thinking about the fastest way to bring them into the clinic," said Edward Stuart, chief business officer of U3.

In May 2001, Ullrich decided to set up a new company and persuaded Stuart and Mike Rothe to join the new venture from DeveloGen AG (Goettingen, Germany). "Within four months,...

Read the full 754 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >